Document is current
Any future updates will be listed below
-
Authors
de Almeida Baptista, Marcella Vassão
da Silva, Laís Teodoro
Samer, Sadia
Oshiro, Telma Miyuki
Shytaj, Iart Luca
Giron, Leila B.
Pena, Nathalia Mantovani
Cruz, Nicolly
Gosuen, Gisele Cristina
Ferreira, Paulo Roberto Abrão
Cunha-Neto, Edécio
Galinskas, Juliana
Dias, Danilo
Sucupira, Maria Cecilia Araripe
de Almeida-Neto, Cesar
Salomão, Reinaldo
da Silva Duarte, Alberto José
Janini, Luís Mário
Hunter, James R.
Savarino, Andrea
Juliano, Maria Aparecida
Diaz, Ricardo Sobhie http://orcid.org/0000-0002-8395-7304
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct02961829 at ClinicalTrials.govDocuments that mention this clinical trial
Immunogenicity of personalized dendritic-cell therapy in HIV-1 infected individuals under suppressive antiretroviral treatment: interim analysis from a phase II clinical trial
https://doi.org/10.1186/s12981-021-00426-z
-
Funding
Funding for this research was provided by:
FAPESP (2013/11323-5)
CNPq (CNPq)
CNPq/DECIT (441817/2018-1)
ViiV Healthcare
- License Information
-
More Information
Article History
Received: 7 September 2021
Accepted: 16 December 2021
First Online: 12 January 2022
Declarations
:
: The protocol was approved by human subjects review committees (Approval #180727 of December 21th 2013), and all subjects gave written, informed consent.
: Authors give consent to AIDS RESEARCH and THERAPY to publish this work upon acceptance.
: ILS, AS, and RSD have a patent application for Dendritic-cell therapy.
